Search
Now showing items 1-10 of 11
Understanding, treating, and renaming grandiosedelusions: A qualitative study
(2019-11)
Background.Grandiose delusions are arguably the most neglected psychotic experience in research.
Objectives.We aimed to discover from patients: whether grandiose delusions have harmful consequences; the psychological ...
The comments of voices on the appearance of patients with psychosis: ‘the voices tell me that I am ugly’
(2019-09)
Background:There are high rates of obesity and low self-esteem in patients with psychosis. The occurrence of negative voice content directly about appearance is therefore plausible. Derogatory comments about appearance are ...
Clozapine-induced pericarditis: an ethical dilemma
(2019-06)
Clozapine is an atypical antipsychotic used most frequently in the management of treatment-resistant schizophrenia, where severely unwell patients have failed to respond to standard antipsychotic therapy. Clozapine is ...
The effect of a genetic variant at the schizophrenia associated AS3MT/BORCS7 locus on striatal dopamine function: A PET imaging study
(2019)
One of the most statistically significant loci to result from large-scale GWAS of schizophrenia is 10q24.32. However, it is still unclear how this locus is involved in the pathoaetiology of schizophrenia. The hypothesis ...
Comparative effects of 18 antipsychotics on metabolic function in schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis
(2019-10)
Background: Antipsychotic-treatment is associated with metabolic disturbance. However, the relative degree to which metabolic alterations occur in treatment with different antipsychotics remains unclear. Furthermore, ...
Hummingbird Study: a study protocol for a multicentre exploratory trial to assess the acceptance and performance of a digital medicine system in adults with schizophrenia, schizoaffective disorder or first-episode psychosis
(2019-06)
Introduction: In patients with schizophrenia, medication adherence is important for relapse prevention, and effective adherence monitoring is essential for treatment planning. A digital medicine system (DMS) has been ...
Disrupted‐in‐schizophrenia 1 functional polymorphisms and D2/D3 receptor availability: A [11C]‐(+)‐PHNO imaging study
(2019-07)
The disrupted‐in‐schizophrenia 1 (DISC1) protein has been implicated in a range of biological mechanisms underlying chronic mental disorders such as schizophrenia. Schizophrenia is associated with abnormal striatal dopamine ...
Hebephrenia is dead, long live hebephrenia, or why Hecker and Chaslin were on to something
(2019-05-03)
Since its first description in 1863, ‘hebephrenia’ has highlighted a group of patients characterised by an early onset of illness, formal thought disorder, bizarre behaviour and incongruent emotional expression. A proportion ...
The tail wagging the dog: the diagnostic accuracy of first rank symptoms COMMENTARY ON… COCHRANE CORNER
(2019-10)
Outcomes for people with schizophrenia are improved by expedient diagnosis and specific treatment. ICD-11 and DSM-5 have reduced the importance of Schneider's first rank symptoms (FRS) in the diagnosis of schizophrenia; ...
Is adjunctive CBT really effective for schizophrenia?
(2019-09)
Although antipsychotic medication remains the
mainstay of treatment for schizophrenia, medications
alone are not always successful. Cognitive–
behavioural therapy (CBT) is recommended as an
adjunct to pharmacological ...